Background: Longevinex ® (L/RV) is a low dose hormetic over-the-counter (OTC) oral resveratrol (RV) based matrix of red wine solids, vitamin D3 and inositol hexaphosphate (IP6) with established bioavailability, safety, and short-term efficacy against the earliest signs of human atherosclerosis, murine cardiac reperfusion injury, clinical retinal neovascularization, and stem cell survival. We previously reported our short-term findings for dry and wet age-related macular degeneration (AMD) patients. Today we report long term (two to three year) clinical efficacy. Methods: We treated three patients including a patient with an AMD treatment resistant variant (polypoidal retinal vasculature disease). We evaluated two clinical measures of ocular structure (fundus autofluorescent imaging and spectral domain optical coherence extended depth choroidal imaging) and qualitatively appraised changes in macular pigment volume. We further evaluated three clinical measures of visual function (Snellen visual acuity, contrast sensitivity, and glare recovery to a cone photo-stress stimulus). Results: We observed broad bilateral improvements in ocular structure and function over a long time period, opposite to what might be expected due to 
Introduction
There is emerging interest in applying epigenetics to the field of ophthalmology, ocular health status, function, and disease(s). Epigenetic modification using small molecular weight nutrients has been discussed in cancer and heart disease, suggesting a potential for cardio-protection against ischemiareperfusion injuries [1] . However, there remains a dearth of publications applying epigenetics to clinical ophthalmology. There are fewer than a hundred accumulated published articles on PubMed concerning epigenetic regulatory mechanisms and ocular development, health, and diseases.
Epigenetics involves modifications of genetic material that does not impact DNA nucleotide sequences. The complex epigenome results in gene expression and/or gene silencing. While classical genetics concerns itself with inherited mutations (i.e., nucleotide substitutions, omissions), epigenetics involves the variable protein expression that facilitates cellular adaptability, enhancing stem cell survival, and tissue regeneration as manifested through the three specific mechanisms:
(1) DNA methylation, the addition of a methyl group (M) to the DNA base cytosine (C) from folate (B9) and B12, is most active during embryogenesis and early childhood. (2) Histone modification include protein spools that control gene expression by winding or unwinding DNA strands around histone bodies by such natural/dietary histone deacetylase (HDAC) inhibitors as sulforaphane in cruciferous vegetables, diallyl disulfide in garlic, nigella sativa in black cumin seed oil, and resveratrol (RV) in red wine. (3) MicroRNA, short 22 base pair strands of RNA that mesh with messenger RNA, silences a segment of genes during translation. Therefore, microRNAs block the protein-making ability of gene(s). MicroRNA is called the "guiding hand of the human genome" [2] .
Significantly, these processes are controlled by environmental cues such as temperature, radiation, oxygen deprivation, food or food deprivation, (the latter doubling the healthspan and lifespan of lab animals as first demonstrated by Clive McCay in the 1930s) [3] , as well as provision of small molecular weight molecules in nutrients, such as allicin (garlic) and RV (red wine).
Epigenetic mechanisms have great potential to improve the status and function of ocular tissue. Agerelated macular degeneration (AMD) is one of the leading causes of progressive and irreversible vision loss in Western societies. AMD can progress typically from dry (non-exudative) to wet (exudative) form, where the wet form is often visually catastrophic. AMD is distinguished from genetically inherited forms of retinal disease such as Leber's and Stargardt's hereditary retinal dystrophies. This multifactorial aging disorder involves a combination of aging, polygenetic susceptibility genes, and myriad environmental factors, such as smoking and obesity. Epigenetic modifications of the genome modulate this phenotypical variability [4] .
RV, a non-flavonoid polyphenol phytoalexin toxin, is produced in response to infection in plants, such as Vitis vinifera (a grape) when cultivated in stressful conditions, such as cold or lack of light (i.e., northern altitudes) [5] . This small molecule (molecular weight 228 Daltons) enters all cells, does not need to be nanosized, and acts as a dietary histone deacetylase inhibitor, altering the winding and modulating protective pathways against oxidative stress, DNA damage, excitotoxicity, apoptosis, and inflammation. The activity of RV has been linked to cell-surface receptors, membrane signaling pathways, intracellular signal-transduction machinery, nuclear receptors, gene transcription, and metabolic pathways [6] . RV has germane ophthalmologic biological actions, which include antiangiogenesis activity and choroidal vasorelaxation [7] . Numerous animal studies have demonstrated that this polyphenol holds promise against numerous age-associated diseases including cancer, diabetes, Alzheimer, and cardiovascular and pulmonary diseases [5] .
Short-term anti-neovascular effects of Longevinex (L/RV), a resveratrol-containing supplement, on AMD patients have been published [8] , and further mechanistic validation of RVs' suppression of VEGF by human RPE cells has recently been published [9] . We present our clinical experience in the clinic over a multi-year period.
Experimental Section

Selecting an Oral OTC-RV AMD Supplement with Established Bioavailability and Short-Term Efficacy
There is a false concern over RVs' short half-life (minutes) and its lack of bioavailability. Rapid conjugation with glucuronate and sulfate during hepatic detoxification dramatically extending its half-life to 9 h rather than minutes [10] . Generic RV can be photo-isomerized from trans to cis RV by exposure to ultraviolet radiation. For these reasons we selected a commercially available brand of resveratrol that had been stabilized via microencapsulation and tested and shown to work superiorly to plain resveratrol and has undergone toxicity testing [11] . L/RV, an OTC oral RV-based supplement, contains microencapsulated/microionized RV and a blend of red wine polyphenols, primarily quercetin, along with vitamin D3, and inositol hexaphosphate (IP6). The process of microencapsulation and miconization of trans-RV enhances RV stability to light, heat, and oxygen, while micronization drastically increases blood concentration, lifespan, and epigenetic biological potency.
Studies have shown that quercetin enhances the immediate bioavailability of RV (RV makes more passes through the liver before complete metabolization). Vitamin D3 controls a variety of genes involved in innate immunity, inflammation, and vascular calcification and has recently emerged as an important nutrient (prohormone) against AMD [12, 13] . IP6 (inositol hexaphosphate) from rice bran is nature's divalent mineral binder (i.e., iron and copper) and replaces the need for phlebotomy or chelation, in diseases of iron mismanagement [14] . Multiple polyphenols, in general, and L/RV in particular, exhibit synergistic rather than just additive biological and epigenetic effects [15] .
The published synergistic actions of L/RV itself, and/or reference to a component within L/RV, are found at Longevinex ® [16] , and extend well beyond RV to include:
( Short-term L/RV anti-VEGF type improvements even in octogenarians with ocular pathology, was recently documented at our medical center [8] . L/RV acts as an anti-oxidant to reduce oxidative stress, and our group was also the first to show minimized lipofuscin epoxidation in an octogenarian AMD patient presumably by down-regulation of reactive oxygen species, sparing aging pigment epithelial cells from DNA damage and premature apoptosis, as well as promoting stem cell survival [17] . L/RV activates miRNA genes in murine models nine-fold greater than RV alone [18] . Through such effects, L/RV may outperform anti-VEGF monoclonal antibodies. This can be accomplished because L/RV addresses the known reason why anti-VEGF drugs fail (macrophage polarization via KLF4) and L/RV has superior down-regulation of miRNA 20b expression 1366 times [18] compared to plain RV. The miRNA 20b fragment controls the hypoxia-inducing factor-1 (HIF1) and the VEGF gene, decreasing VEGF to prevent choroidal neovascularization and angiogenesis in as little as one week [8] . This mechanism prevents the conversion from dry to wet AMD.
We have also clinically shown, using spectral domain OCT imaging, that L/RV targets and promotes RPE stem cells to regenerate within the living human eye of another octogenarian (88-year-old) AMD patient, over a 20-week period [19] . Unfortunately, large scale L/RV human clinical trials are lacking. However, a clinical trial in Japan, has demonstrated cardiovascular benefits of L/RV through improvements in endothelial function of adults with metabolic syndrome receiving standard treatment [20] .
Dosage and Clinical Safety Considerations
RV characteristically exhibits a U or J shaped risk curve with hormetic low dose benefits and negative effects at high doses [1] . In rodents it is cardio-protective between 175 and 350 mg human equivalent dose (HED), and cytotoxic at 10-times higher doses between 1750 and 3500 mg HED, and a dose of 3500 mg RV was universally lethal to rat hearts [1] . A Glaxo Smith Kline phase 2 human clinical trial of RV in multiple myeloma patients was suspended in 2010 because several patients developed kidney failure at 5000 mg.
In contradistinction, L/RV has been shown to exhibit a biologically unique L-shaped risk curve and unparalleled margin of safety at high doses up to 2800 mg HED. This margin of safety is clearly superior to RV alone. L/RV passed toxicity testing, meeting the New Dietary Ingredient guidelines described by the FDA [11, 21] . This dietary supplement exhibits good safety and the recommended dosage (one capsule per day) and has not produced major side effects among non-anemic subjects over a ten-year period of commercial use [16] .
Veteran patients at the James A Lovell Federal Health Care Center, for whom other therapeutic measures had been exhausted (ARED and AREDS II supplements, anti-VEGF treatments, etc.), were prescribed one capsule containing low dose nutrients (100 mg trans RV) daily and followed clinically. L/RV was compassionately provided when no other options were available beyond the Vision Impairment Service Teams' low vision and blind-rehabilitation services.
Consent/IRB
An Investigational New Drug (IND) submission is not required to use a marketed product as a part of medical practice for individual patients. However, supervision was requested and approved by the Chief of Staff and IRB (Hines DVA, Chicago, IL, USA).
Participants
We compiled data from three male AMD patients who were on the L/RV matrix for multi-year periods using an enhanced clinical visual function protocol developed at our medical center [22] . 
Methodology
Retina/choroid structure modalities: We employ the spectral (visible/IR) separation images for AMD patients because, compared to traditional fundus photographs, there is high sensitivity in identifying intra-retinal pathology (retinal drusen), the critical underlying blood supply underneath the retina (i.e., the choroidal network that becomes less dense in AMD), as well as MPOD typically diminished in AMD.
Traditional colored fundus photographs are also derived through wavelength recombination.
Visual function modalities:
1. Visual Acuity (VA-high contrast, high spatial frequency): The clinical best-refracted Snellen acuity was taken in a semi-darkened room using a digital Smart Systems ® projection system (M and S Technologies, Skokie, IL, USA). 2. Contrast Sensitivity (CSF-all contrasts, all spatial frequencies): The contrast sensitivity function (CSF), a measure of how an eye sees large objects (low spatial frequencies at 1.5 and 3 cycles/degree) and small objects such as Snellen letters (higher spatial frequencies, i.e., 18 cycles/degree)-x axis, at differing contrasts-y axis. The area under the curve of the resulting CSF at five spatial frequencies was measured with the validated instrument (Functional Vision Analyzer ® (Stereo Optical, Chicago, IL, USA) with best refraction at each visit. 
Results
Cases 1-3 present patients afflicted with AMD that have taken L/RV over a multi-year period. All other curative measures had been exhausted for these patients, or the patient was either refused intra-vitreal injections, treatment resistant, or classified as non-candidates by conventional retinal ophthalmologic evaluation.
Case 1: A 64-year-old patient with atrophic AMD and diabetes type 2 taking L/RV for 2.5 years. We observed diminishment of retinal lipofuscin, enhanced choroidal thickness (perfusion), qualitatively increased visualized macular pigment volume, CSF, and shortened GR time. Figure 1 depicts decreased RPE FAF over time reflecting lipofuscin resolution in both retinas. Figure 2 shows choroidal thickening, opposite of an expected age-related decline. Figure 3 depicts dramatic improvements in macular pigment volume with no change in carotenoid/omega-3 supplementation. These factors denote improved ocular structure. Figure 4 depicts better CSF and GR over time. Cardiovascular and serum parameters were also reviewed. We observed improvements in HbA1C, body mass index (BMI), blood pressure (BP), pulse, and pulse pressure ( Table 1 ). The following measurements were taken during patient visits before L/RV use (n = 4 from 9/29/10 to 12/9/10) and patient visits after L/RV use (n = 16 from 2/25/11 to 6/12/13); A1C levels decreased by 0.36 mg%; BMI decreased by 1.87; systolic BP decreased by 13.37 mmHg and diastolic BP decreased by 2.69 mmHg; pulse decreased by 9.87 beats/min; pulse pressure decreased by 10.69 mmHg. The patient has been pleased with both his enhanced vision and improved cardiovascular health. Case 2: An 89-year-old Caucasian male with atrophic AMD who has been on L/RV for 2.5 years. We similarly observed a decrease in lipofuscin accumulation ( Figure 5 ), an increase in choroidal thickness (Figure 6 ), stabilization of visualized macular pigment volume (Figure 7) , stabilization of GR right eye, better GR left eye, and better CSF (Figure 8 ). The patient continues to maintain an unrestricted driver's license, despite his age and expected pathologic decline. Better clinical perfusion of the posterior retina is surmised. 
Discussion
Diminishment of lipofuscin autofluorescence, as seen in Case 1 and 2, is pathognomonic of healthy retina-RPE-choroidal tissue, as is denser macular pigment (Case 1 and 3) . The choroid typically thins with age and at a faster rate in AMD [23, 24] , yet in our patients, thickening was observed (Cases 1-3) . Taken together, these clinical observations are consistent with the murine cardiac reperfusion experiments performed under the direction of Professor Depak Das at the University of Connecticut's Cardiovascular Research Center [25] [26] [27] , as well as a human clinical trial from Japan demonstrating superior vascular health in patients taking L/RV even for short periods of time [20] . Furthermore, the improved contrast sensitivity and glare recovery we observe are consistent with these improved structural observations. Foveal health is ultimately affected by drusen deposits that degrade the function and number of cone photoreceptors. Biochemical signs of photoreceptor degeneration, such as decreased expression of synapse-associated proteins and increased expression of stress-response molecules, are seen in AMD patients. The salutary broad and comprehensive effects of L/RV on choroidal thickness, anti-inflammatory markers, regulation of divalent metals, the vitamin D pathway, cellular stress, toxicity genes, up-regulation of Nrf2, and even macular pigment volume appears to ultimately retard degeneration of photoreceptors.
Epigenetics is at the epicenter of modern medicine. It is the study of non-DNA sequence-related heredity that helps explain the relationship between an individual's genetic background, the environment, aging, and disease. In 2013, researchers from a multinational consortium reported results on 19 common susceptibility loci from DNA analyses on nearly 80,000 people, and in aggregate, these loci explain only 10%-30% of the phenotypic variation of AMD [28, 29] . The epigenetic state varies among tissues during a lifetime, whereas the DNA sequence remains essentially the same. Dietary recommendations or lack thereof, changes ones DNA and its translation. Clinical reports from our medical center provides us reason to believe that L/RV is beneficial because it reestablishes retinal architecture, decreases lipofuscin accumulation, increases choroidal thickness (perfusion), increases macular pigment volume, improves contrast sensitivity, decreases glare recovery time, and improves visual function-all ostensibly through improved retinal-RPE-choroidal cellular health. These observed clinical benefits in ocular structure and function are seen bilaterally in both eyes with further synergistic effects observed in cardiovascular parameters (i.e., Case 1), consistent with animal data, and the only human clinical trial to date [20, [23] [24] [25] .
Conclusions
Randomized placebo controlled ocular-cardiovascular molecular medicine clinical studies are warranted to confirm the proposed dual cardiovascular and ophthalmologic benefits of low-dose epigenetic nutriceutical intervention beyond AREDS II supplementation.
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